

**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1 – 3 (cancelled)

Claim 4 (currently amended): A glycoprotein extracted from blood serum, intercellular space of tissues of liver, thymus or eye of human beings and animals by using isoelectric focusing, the glycoprotein being soluble in saturated (100%) solution of ammonium sulphate, having apparent molecular weight of 10-45 kDa and having specific biological activity to influence viscoelastic properties of hepatocyte membranes in ultra low doses from  $10^{-12}$  to  $10^{-29}$  mol/liter, said specific biological activity to influence viscoelastic properties of hepatocyte membranes is determined by the amount of cellular nuclei released during dispersing according to the formula:  $E_a = 200\% - (N_{on}/N_k) \times 100\%$ , where  $E_a$  is biological effect caused by the glycoprotein,  $N_{on}$  and  $N_k$  are the amount of cell nuclei released from 1 mg of tissue culture with the glycoprotein and tissue culture without the glycoprotein, respectively and lower.

Claim 5 (previously presented): A pharmaceutical composition comprising the glycoprotein of claim 4 in an effective amount and a pharmaceutically acceptable carrier.

Claim 6 (previously presented): A method of using the glycoprotein of claim 4 comprising the step of administering the glycoprotein to a subject as a medicinal agent.

Claims 7 – 9 (cancelled)